Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy

Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy

BackgroundCutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer whose incidence is growing parallel to the lengthening of the average lifespan. Cemiplimab, an antiPD-1 monoclonal antibody, is the first approved immunotherapy for patients with locally advanced CSCC (laCSCC) o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sabino Strippoli, Annarita Fanizzi, Davide Quaresmini, Annalisa Nardone, Andrea Armenio, Francesco Figliuolo, Raffaele Filotico, Livia Fucci, Fabio Mele, Michele Traversa, Federica De Luca, Elisabetta Sara Montagna, Eustachio Ruggieri, Simona Ferraiuolo, Francesco Macina, Stefania Tommasi, Angela Monica Sciacovelli, Ivana De Risi, Anna Albano, Raffaella Massafra, Michele Guida
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
cemiplimab
advanced cutaneous squamous cell carcinoma
checkpoint inhibitors
elderly patients
immunocompromised patients
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/e3cb353df58947c7904f8a685506ef5d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares